DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for popliteal pterygium syndrome — screening already-approved drugs against its 2-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease modulePopliteal pterygium syndrome maps to a 2-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for popliteal pterygium syndrome is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
What the evidence adds up to
No drug treatment is described in any of the four abstracts. The 1990 paper reviews a family with popliteal pterygium syndrome and notes that the mother had a repaired cleft palate and toe syndactyly, but the baby presented with most major signs of the syndrome. The authors discuss variable expression and biases in earlier case reporting. The 1984 paper describes a male infant with the severe autosomal recessive form (Bartsocas-Papas syndrome) who had all phenotypic manifestations at birth; the authors conclude this is a distinct genetic entity. The 1992 report presents a new case with the complete PPS complex plus previously undescribed findings: a sinus of the upper lip, extreme hypoplastic prolabium with aplasia of the vestibule, and a velar pterygium. A treatment protocol is mentioned but no drug is named. The 2014 case report identifies a Moroccan infant with the c.250C>T; p.Arg84Cys mutation of the IRF6 gene on 1q32.2, confirming autosomal dominant inheritance. The diagnosis allowed management and genetic counselling, but again no drug therapy is discussed.
Across all four papers, the only interventions mentioned are surgical repair (cleft palate in the 1990 mother) and a treatment protocol in the 1992 report whose contents are not specified. No drug, no response rate, no survival data, and no molecular therapy appear in any abstract. The condition is defined entirely by congenital malformations—orofacial, musculoskeletal, genitourinary—and the literature focuses on genetic diagnosis, syndrome delineation, and surgical management.
What is missing is any clinical trial, any drug repurposing attempt, any preclinical model testing a pharmacological agent, and any patient stratification beyond genetic subtype. No funding for drug development in this ultra-rare syndrome is mentioned. Without a molecular target that can be modulated by a small molecule or biologic, and without any evidence that postnatal drug treatment can alter the fixed structural anomalies of PPS, the possibility of a drug intervention remains entirely theoretical.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
American Journal of Medical Genetics · 1990 · 29 citations
The popliteal pterygium syndrome: Report of a new family and review of the literature
AbstractThis paper reports on a family with popliteal pterygium syndrome (PPS), which was ascertained through a baby with most of the major signs of the syndrome. The mother, who had a repaired cleft palate and toe syndactyly, had been aware that her syndactyly was familial, but her unpreparedness for the birth of a child with PPS led to interest in, and a subsequent review of, the differnetial diagnosis and the variable expression of the clinical manifestations of this syndrome. Upon review, some earlier reported cases were excluded as PPS, and certain ascertainment and reporting biases that could affect such an analysis were considered.
American Journal of Medical Genetics · 1984 · 27 citations
The Bartsocas‐Papas syndrome: Autosomal recessive form of popliteal pterygium syndrome in a male infant
AbstractWe report on an additional patient with the severe autosomal recessive form of the popliteal pterygium syndrome. The patient was diagnosed at birth and had all of the phenotypic manifestations of this rare syndrome. Clinical findings and natural history suggest this is a distinct genetic entity.
The Cleft Palate-Craniofacial Journal · 1992 · 7 citations
Popliteal Pterygium Syndrome with Special Consideration of the Cleft Malformation: Case Report
AbstractThis report describes a new case of popliteal pterygium syndrome (PPS) and also a treatment protocol. The patient presented with the complete complex of PPS and additional abnormalities that have not been described in the literature: a sinus of the upper lip, an extreme hypopoplastic prolabium with aplasia of the vestibule in this area, and a velar pterygium.
Journal of Medical Case Reports · 2014 · 7 citations · open access
Clinical and molecular findings in a Moroccan patient with popliteal pterygium syndrome: a case report
AbstractINTRODUCTION: Popliteal pterygium syndrome is a congenital malformation that includes orofacial, musculoskeletal and genitourinary anomalies. It is a rare autosomal dominant disorder due to a mutation of the IRF6 gene on 1q32.2. CASE PRESENTATION: A one-month-old Moroccan baby boy was diagnosed with typical features of popliteal pterygium syndrome and carried the c.250C>T; p.Arg84Cys mutation of the IRF6 gene. CONCLUSIONS: We report on the first description of a Moroccan popliteal pterygium syndrome patient. This diagnosis allowed us to provide an appropriate course of management to the patient and offer genetic counseling to his family.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
